Christie Ballantyne
Christie Ballantyne
Verified email at
Cited by
Cited by
Heart disease and stroke statistics—2017 update: a report from the American Heart Association
EJ Benjamin, MJ Blaha, SE Chiuve, M Cushman, SR Das, R Deo, ...
circulation 135 (10), e146-e603, 2017
Antiinflammatory therapy with canakinumab for atherosclerotic disease
PM Ridker, BM Everett, T Thuren, JG MacFadyen, WH Chang, ...
New England journal of medicine 377 (12), 1119-1131, 2017
From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I
M Naghavi, P Libby, E Falk, SW Casscells, S Litovsky, J Rumberger, ...
Circulation 108 (14), 1664-1672, 2003
Biological, clinical and population relevance of 95 loci for blood lipids
TM Teslovich, K Musunuru, AV Smith, AC Edmondson, IM Stylianou, ...
Nature 466 (7307), 707-713, 2010
Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial
SE Nissen, SJ Nicholls, I Sipahi, P Libby, JS Raichlen, CM Ballantyne, ...
Jama 295 (13), 1556-1565, 2006
Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia
DL Bhatt, PG Steg, M Miller, EA Brinton, TA Jacobson, SB Ketchum, ...
New England Journal of Medicine 380 (1), 11-22, 2019
Effects of dalcetrapib in patients with a recent acute coronary syndrome
GG Schwartz, AG Olsson, M Abt, CM Ballantyne, PJ Barter, J Brumm, ...
New England Journal of Medicine 367 (22), 2089-2099, 2012
Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association
M Miller, NJ Stone, C Ballantyne, V Bittner, MH Criqui, HN Ginsberg, ...
Circulation 123 (20), 2292-2333, 2011
Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial)
PH Jones, MH Davidson, EA Stein, HE Bays, JM McKenney, E Miller, ...
The American journal of cardiology 92 (2), 152-160, 2003
Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk In Communities …
SJ Hwang, CM Ballantyne, AR Sharrett, LC Smith, CE Davis, AM Gotto Jr, ...
Circulation 96 (12), 4219-4225, 1997
Efficacy and safety of evolocumab in reducing lipids and cardiovascular events
MS Sabatine, RP Giugliano, SD Wiviott, FJ Raal, DJ Blom, J Robinson, ...
New England Journal of Medicine 372 (16), 1500-1509, 2015
The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study
AM McNeill, WD Rosamond, CJ Girman, SH Golden, MI Schmidt, HE East, ...
Diabetes care 28 (2), 385-390, 2005
Comprehensive overview of nursing and interdisciplinary rehabilitation care of the stroke patient: a scientific statement from the American Heart Association
EL Miller, L Murray, L Richards, RD Zorowitz, T Bakas, P Clark, ...
Stroke 41 (10), 2402-2448, 2010
Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein (a), apolipoproteins AI and B, and HDL density subfractions: The …
AR Sharrett, CM Ballantyne, SA Coady, G Heiss, PD Sorlie, D Catellier, ...
Circulation 104 (10), 1108-1113, 2001
Low-grade systemic inflammation and the development of type 2 diabetes: the atherosclerosis risk in communities study
BB Duncan, MI Schmidt, JS Pankow, CM Ballantyne, D Couper, A Vigo, ...
Diabetes 52 (7), 1799-1805, 2003
Carotid intima-media thickness and presence or absence of plaque improves prediction of coronary heart disease risk: the ARIC (Atherosclerosis Risk In Communities) study
V Nambi, L Chambless, AR Folsom, M He, Y Hu, T Mosley, K Volcik, ...
Journal of the American College of Cardiology 55 (15), 1600-1607, 2010
Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association
MA Hlatky, P Greenland, DK Arnett, CM Ballantyne, MH Criqui, ...
Circulation 119 (17), 2408-2416, 2009
Effect of two intensive statin regimens on progression of coronary disease
SJ Nicholls, CM Ballantyne, PJ Barter, MJ Chapman, RM Erbel, P Libby, ...
New England Journal of Medicine 365 (22), 2078-2087, 2011
Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo …
PM Ridker, JG MacFadyen, T Thuren, BM Everett, P Libby, RJ Glynn, ...
The Lancet 390 (10105), 1833-1842, 2017
Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial
SJ Nicholls, R Puri, T Anderson, CM Ballantyne, L Cho, JJP Kastelein, ...
Jama 316 (22), 2373-2384, 2016
The system can't perform the operation now. Try again later.
Articles 1–20